On August 5, 2026, the Hong Kong stock market experienced a dramatic intraday reversal. The Hang Seng Index opened lower in the morning and dipped to 21,230 points, weighed down by an overnight pullback in US tech stocks and geopolitical uncertainties. However, the afternoon saw a sharp turnaround, driven by strong rallies in mainland property and pharmaceutical-biotech sectors. The HSI quickly turned positive and climbed steadily, closing at 21,520 points, up 0.9%, with turnover expanding to HK$145 billion, about 12% higher than the previous day.

Mainland Property Stocks Surge: Policy Expectations and Sales Data Converge

The standout sector today was mainland property stocks. In early afternoon trading, Country Garden Services (6098.HK) led the charge, surging over 8% at one point, followed by Sunac China (1918.HK) and China Overseas Land & Investment (0688.HK), driving the Hang Seng Properties Index up 2.3%.

Market rumors suggest regulators are preparing a new round of property support policies, including further easing of purchase restrictions in first-tier cities and reducing down payment ratios for second homes. While no official confirmation has been made, multiple brokerages noted that July sales data from top 100 developers showed a 5% month-on-month rebound, with the year-on-year decline narrowing to single digits, signaling a potential industry bottom.

"Mainland property stocks are currently trading at historically low valuations, with P/E ratios generally at 4-6x and dividend yields exceeding 5%," a CICC analyst wrote in a report today. "Once policy signals become clear, the sector could experience a Davis Double Play." Southbound net buying in the property sector reached approximately HK$1.2 billion today, accounting for over one-third of the total half-day net inflow.

Pharma Sector Breaks Out: Faster Innovative Drug Approvals Catalyze Rally

The pharmaceutical sector also delivered a standout performance. The Hang Seng Healthcare Index rose 2.8%, with BeiGene (6160.HK) up 5.2%, Innovent Biologics (1801.HK) up 4.7%, and WuXi AppTec (2359.HK) up 3.9%.

The catalyst was a morning announcement by the National Medical Products Administration: effective immediately, eligible innovative drug clinical trial applications will be subject to a "tacit approval" system, shortening the review period from 60 to 30 working days. The market interpreted this as a significant boost for accelerating innovative drug launches and encouraging R&D.

"This policy directly reduces time costs and uncertainty for innovative drug companies, benefiting leading firms with rich pipeline reserves the most," a private equity healthcare fund manager told Agu Wall Street. "We expect a valuation recovery wave for Hong Kong-listed pharma stocks in the second half, especially for biotech companies with stable cash flow and high R&D investment."

Capital Flows: Southbound Funds Buy Decisively, Foreign Investors Split

Southbound net buying reached HK$3.15 billion in the half-day, continuing the inflow trend since July. By individual stock, Tencent (0700.HK) led with net buying of HK$620 million, followed by Meituan (3690.HK) at HK$480 million and CNOOC (0883.HK) at HK$350 million. Notably, southbound interest in high-dividend plays remained strong, with PetroChina (0857.HK) and China Shenhua Energy (1088.HK) also seeing net buying.

However, foreign investor activity was mixed. By the close, northbound funds (Shanghai and Shenzhen Connect) recorded net selling of A-shares worth about RMB 1.5 billion, while overseas funds flowing into Hong Kong via Stock Connect were relatively cautious. UBS issued a report today noting that while Hong Kong valuations are attractive, short-term attention must be paid to the Fed's rate hike path and RMB exchange rate volatility risks.

HSI Technicals: Watch 21,800 Resistance After V-Shaped Rebound

From a technical perspective, the HSI found support near 21,200 points today and rebounded quickly, closing above the 21,500-point psychological level, indicating building bullish momentum. The daily MACD is about to form a golden cross, and the RSI has recovered to around 55, suggesting strong short-term momentum.

However, the 21,800-22,000 zone represents a previous high-volume area and the 60-day moving average, posing significant resistance. If turnover can sustain above HK$150 billion and leading sectors like property and pharma remain active, the HSI could challenge the 22,000 mark by mid-August. Conversely, if volume shrinks or policy expectations fade, the index may return to a 21,000-21,500 range.

Hong Kong Market Outlook: Structural Opportunities Remain, Focus on Three Themes

Based on today's market action and institutional views, Agu Wall Street identifies three structural opportunities for the Hong Kong market in August:

  • Mainland Property and Infrastructure Chain: Strong policy support expectations, combined with the approaching traditional "Golden September, Silver October" peak season, could benefit post-cycle property sectors like building materials and home furnishings.
  • Pharmaceutical Innovation: Faster approvals and aging demographics make innovative drugs, CXO, and medical devices attractive for medium-to-long-term allocation.
  • High-Dividend Defensives: Against a backdrop of global rate declines, Hong Kong energy and utility high-dividend plays remain top picks for stable capital, especially for long-term funds like insurers and pension funds among southbound investors.

Risk Warning: Investors should be alert to potential shocks to Hong Kong liquidity from unexpectedly aggressive Fed tightening, geopolitical risks, and sharp fluctuations in the RMB exchange rate.

(Agu Wall Street, Hong Kong, August 5, 2026)